COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response

Multiple randomized, controlled clinical trials have yielded discordant results regarding the efficacy of convalescent plasma in outpatients, with some showing an approximately 2-fold reduction in risk and others showing no effect. We quantified binding and neutralizing antibody levels in 492 of the...

Descripción completa

Detalles Bibliográficos
Autores principales: McDyer, John F., Azimpouran, Mahzad, Durkalski-Mauldin, Valerie L., Clevenger, Robert G., Yeatts, Sharon D., Deng, Xutao, Barsan, William, Silbergleit, Robert, El Kassar, Nahed, Popescu, Iulia, Dimitrov, Dimiter, Li, Wei, Lyons, Emily J., Lieber, Sophia C., Stone, Mars, Korley, Frederick K., Callaway, Clifton W., Dumont, Larry J., Norris, Philip J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174456/
https://www.ncbi.nlm.nih.gov/pubmed/36862515
http://dx.doi.org/10.1172/jci.insight.167890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174456/
https://www.ncbi.nlm.nih.gov/pubmed/36862515
http://dx.doi.org/10.1172/jci.insight.167890

Ejemplares similares